Zacks.com on MSN12h
Catalent Stock Flat Following the Sell Agreement With Ardena
CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.
BioSpace18h
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...
FiercePharma2d
Catalent offloads New Jersey manufacturing plant, HQ to Belgian CDMO Ardena
Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...
bovnews1d
Stock Shock: The Unpredictable Rise and Fall of CTLT—What’s Driving the Drama?
On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...
BioSpace5d
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...
Catalent, Inc. (NYSE:CTLT) Receives $59.83 Average Target Price from Analysts
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight ...
STAT7d
Warren urges FTC to probe deal that would give Novo Nordisk control of some Catalent plants
U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent
Somerset facility State-of-the art facility for clinical and commercial manufacturing of oral dosage forms. Ghent, Belgium, ...